Results 41 to 50 of about 530,197 (354)

RETRACTED: Role of miR‐490‐3p in blocking bladder cancer growth through targeting the RNA‐binding protein PCBP2

Kaohsiung Journal of Medical Sciences, 2022
MiR‐490‐3p is regarded as a tumor suppressor in many cancers, but whether miR‐490‐3p is involved in the development of bladder cancer remains unknown. BALB/c nude mice (male, 15–20 g) were used to investigate the role of MiR‐490‐3p in bladder cancer. The
Cun‐Ming Zhang, Li‐De Song, Jun‐Wei Wang, Hai‐Bo Ye, Song Chen   +4 more
doaj   +1 more source

Cystomanometry – One of the Assessment Methods of the Urodynamic Indexes in Patients with Infiltrative Cervical Cancer [PDF]

, 2016
Aim: To evaluate contractile function of urinary bladder in patients with infiltrative cervical cancer after nerve-sparing radical hysterectomy (NSRH).Patients and Methods: Ninety patients with infiltrative cervical cancer were treated with nerve-sparing
Dermenzhy, T. (Tetyana), Iatsyna, O. (Oleksandr), Kabanov, O. (Oleksandr), Nespryadko, S. (Sergey), Svintsitsky, V. (Valentin)   +4 more
core   +2 more sources

Epidemiology of Bladder Cancer [PDF]

Medical Sciences, 2020
Based on the latest GLOBOCAN data, bladder cancer accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. In the United States, bladder cancer is the sixth most incident neoplasm. A total of 90% of bladder cancer diagnoses are made in those 55 years of age and older, and the disease is four times more common in ...
Adam Barsouk, Prashanth Rawla, Sandeep A. Padala, Kalyan Saginala, John Sukumar Aluru, Alexander Barsouk   +5 more
openaire   +3 more sources

Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]

, 2017
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K, Bolzenius, Jennifer, Bowman, Gregory R, Chu, Clarence E, Halstead, Angela M, Kapadia, Chiraag D, Schriefer, Andrew, Wartman, Lukas D   +7 more
core   +2 more sources

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

OncoImmunology, 2019
Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin.
Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney   +11 more
doaj   +1 more source

Integrative Analysis Identified MCT4 as an Independent Prognostic Factor for Bladder Cancer

Frontiers in Oncology, 2021
BackgroundBladder cancer is the 10th most common cancer and most common urothelial malignancy worldwide. Prognostic biomarkers for bladder cancer patients are required for individualized treatment. Monocarboxylate transporter 4 (MCT4), encoded by SLC16A3
Yang Zhao, Bin Zhao, Wei-Hua Yan, Yan Xia, Zhi-Hui Wang, Guo-Yang Zheng, Wen-Da Wang, Yu-Shi Zhang   +7 more
doaj   +1 more source

Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study [PDF]

, 2014
Background: There is evidence that cancer survivors are at increased risk of second primary cancers. Changes in the prevalence of risk factors and diagnostic techniques may have affected more recent risks.<p></p> Methods: We examined the
A Chopra, A Mehnert, Aishah Coyte, C Dong, C Fabbri, C Thellenberg, CH Johnson, D Brewster, D Brewster, D Brewster, D Forman, D Groheux, D Howel, David S Morrison, DM Parkin, DM Parkin, DR Youlden, E Crocetti, E Kellen, EM Ibrahim, F Levi, GB Yang, I Soerjomataram, IARC/ENCR/IACR Working Group, International Agency for Research on Cancer, J Ferlay, J Jegu, J Maddams, JA Atienza, JW Hotchkiss, K Hemminki, K Hemminki, K Moser, L Liu, L Liu, L Mellemkjaer, LJ Rutten, MB Adamo, MH Schmid-Wendtner, Philip McLoone, RE Curtis, S Scholes, X Gao, Y Chen   +43 more
core   +3 more sources

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection

Biomarker Research
Background and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear which type of
Naheema S. Gordon, Elspeth K. McGuigan, Michaela Ondasova, Jennifer Knight, Laura A. Baxter, Sascha Ott, Robert K. Hastings, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Anshita Goel, Minghao Yu, Roland Arnold, Richard T. Bryan, Douglas G. Ward   +14 more
doaj   +1 more source